No data to show
XLON
VRCI
Market cap4mUSD
May 30, Last price
1.25GBP
1D
0.00%
1Q
-56.60%
IPO
-97.28%
Name
Verici Dx Plc
Chart & Performance
P/E
—
P/S
402.68
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1m
Net income
-9m
L-23.11%
CFO
-7m
L-28.88%
Earnings
Jul 14, 2025
Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 1,013 | |||
Cost of revenue | 8,598 | 15,329 | ||
Unusual Expense (Income) | ||||
NOPBT | (7,585) | (15,329) | ||
NOPBT Margin | ||||
Operating Taxes | (48) | |||
Tax Rate | ||||
NOPAT | (7,585) | (15,281) | ||
Net income | (8,734) -23.11% | (11,359) 36.37% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 13,070 | |||
BB yield | -63.50% | |||
| Debt | ||||
Debt current | 163 | 156 | ||
Long-term debt | 917 | 312 | ||
Deferred revenue | ||||
Other long-term liabilities | 544 | |||
Net debt | (1,565) | (9,337) | ||
| Cash flow | ||||
Cash from operating activities | (7,160) | (10,068) | ||
CAPEX | (23) | (1,308) | ||
Cash from investing activities | (231) | (1,308) | ||
Cash from financing activities | (27) | 12,674 | ||
FCF | (6,938) | (16,505) | ||
| Balance | ||||
Cash | 2,645 | 9,805 | ||
Long term investments | ||||
Excess cash | 2,594 | 9,805 | ||
Stockholders' equity | (32,987) | (21,437) | ||
Invested Capital | 37,085 | 33,802 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 170,319 | 164,668 | ||
Price | 0.10 -22.00% | 0.13 -76.42% | ||
Market cap | 16,606 -19.32% | 20,583 -72.60% | ||
EV | 15,041 | 11,246 | ||
EBITDA | (6,756) | (14,689) | ||
EV/EBITDA | ||||
Interest | 29 | 5 | ||
Interest/NOPBT | ||||